Business Milestones
2025.06.11
TAHO Pharmaceuticals Receives Patent Acceptance for TAH3311 Apixaban Oral Dissolving Film in South Africa
TAHO Pharmaceuticals Receives Patent Acceptance for TAH3311 Apixaban Oral Dissolving Film in South Africa
Taipei — June 11, 2025 – TAHO Pharmaceuticals Ltd. announced that the South African Patent Office has officially accepted the patent application for its innovative anticoagulant product, TAH3311, titled "Apixaban Film Product and Uses Thereof." This patent strengthens TAHO’s intellectual property portfolio and provides robust protection for its unique oral dissolving film technology in the South African market.
TAH3311, the world's first Apixaban oral dissolving film, utilizes TAHO’s proprietary Transepithelial Delivery System (TDS). It is designed for patients facing swallowing challenges, such as stroke survivors, elderly individuals, and young children. Unlike conventional anticoagulant tablets, which require grinding into powder, mixing with water, and subsequent cleaning—leading to dosing imprecision and added burden for caregivers—TAH3311 dissolves rapidly in the mouth without water. This enhances medication adherence, simplifies treatment regimens, and offers greater convenience for both patients and caregivers.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills. Proven bioequivalent to Eliquis ® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA 2024)—TAH3311 aims to deliver simpler, more compassionate care worldwide.
Taipei — June 11, 2025 – TAHO Pharmaceuticals Ltd. announced that the South African Patent Office has officially accepted the patent application for its innovative anticoagulant product, TAH3311, titled "Apixaban Film Product and Uses Thereof." This patent strengthens TAHO’s intellectual property portfolio and provides robust protection for its unique oral dissolving film technology in the South African market.
TAH3311, the world's first Apixaban oral dissolving film, utilizes TAHO’s proprietary Transepithelial Delivery System (TDS). It is designed for patients facing swallowing challenges, such as stroke survivors, elderly individuals, and young children. Unlike conventional anticoagulant tablets, which require grinding into powder, mixing with water, and subsequent cleaning—leading to dosing imprecision and added burden for caregivers—TAH3311 dissolves rapidly in the mouth without water. This enhances medication adherence, simplifies treatment regimens, and offers greater convenience for both patients and caregivers.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills. Proven bioequivalent to Eliquis ® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA 2024)—TAH3311 aims to deliver simpler, more compassionate care worldwide.